1. Leukocytes telomere length as a biomarker of adverse drug reactions induced by Osimertinib in advanced non-small cell lung cancer.
- Author
-
Trachu N, Reungwetwattana T, Meanwatthana J, Sukasem C, Majam T, Saengsiwaritt W, Jittikoon J, and Udomsinprasert W
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Telomere Homeostasis drug effects, Biomarkers blood, Drug-Related Side Effects and Adverse Reactions diagnosis, Biomarkers, Tumor blood, Biomarkers, Tumor genetics, Case-Control Studies, Indoles, Pyrimidines, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Acrylamides adverse effects, Leukocytes drug effects, Leukocytes metabolism, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Aniline Compounds adverse effects, Telomere drug effects
- Abstract
This study aimed to measure relative telomere length (RTL) in blood leukocytes of advanced-stage NSCLC patients either with or without Osimertinib-induced ADRs and determine whether RTL could serve as a biomarker of Osimertinib-induced ADRs. Blood leukocytes RTL were measured in 63 advanced-stage NSCLC patients and 62 age-matched healthy controls using real-time polymerase chain reaction. In patients with advanced-stage NSCLC, RTL was significantly shorter than that in healthy controls (P < 0.001). Compared to patients without ADRs and those with mild/moderate ADRs, patients with severe ADRs exhibited significantly decreased RTL (P < 0.001, P < 0.001, respectively). ROC curve analysis uncovered a diagnostic value of RTL as a biomarker of Osimertinib-induced ADRs (AUC = 1.000, P < 0.001). Kaplan-Meier analysis revealed a significant association between shorter RTL and increased cumulative incidence of Osimertinib-induced ADRs in patients with advanced-stage NSCLC (P < 0.001). Shorter RTL in blood leukocytes would reflect the occurrence of Osimertinib-induced ADRs and might emerge as a promising biomarker for identifying advanced-stage NSCLC patients who are at risk of experiencing Osimertinib-induced ADRs, particularly those with severe ADRs., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF